NewLimit really did raise $130 million in a Series B announced on May 6, 2025. But the financing was for preclinical research, not a treatment already shown to reverse aging in people. NewLimit is developing RNA-delivered epigenetic-reprogramming medicines—initially focused on restoring function in older liver cells—and said in June 2026 that it had raised a further $435 million and planned its first human trial for 2027.
What the May 2025 announcement actually covered
NewLimit announced its $130 million Series B on May 6, 2025. Kleiner Perkins led the round. New investors named by the company included Nat Friedman and Daniel Gross’s NFDG, Khosla Ventures, Human Capital and Valor Equity Partners. Returning investors were Dimension, Founders Fund and Brian Armstrong; angel participants included John and Patrick Collison, Fred Ehrsam, Elad Gil, Joshua Kushner, Joe Lonsdale and Garry Tan. The company had previously announced a $40 million Series A in 2023. (NewLimit’s announcement; TechCrunch coverage)
NewLimit said the financing would support medicines intended to add healthy years to life through epigenetic reprogramming. That wording describes a drug-discovery objective, not an approved “anti-aging” product.
Who founded NewLimit?
NewLimit was founded in 2021 by Coinbase co-founder and CEO Brian Armstrong, bioengineer and former GV partner Blake Byers, and computational biologist Jacob C. Kimmel. Kimmel is identified in later company materials as NewLimit’s CEO and president. (formation announcement; 2026 financing announcement)
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsArmstrong is a co-founder and investor. NewLimit’s scientific and operating work is a separate biotech effort, not a Coinbase project, and the company does not attribute the underlying reprogramming science to Armstrong personally.
What “age reversal” means in NewLimit’s science
NewLimit is pursuing cellular rejuvenation, not a way to subtract years from a person’s chronological age. Aging can change epigenetic marks and gene-expression programs that help cells maintain normal function. The company’s hypothesis is that carefully selected combinations of transcription factors can reset some of those programs without fully turning a mature cell into a stem cell.
Its computational system, called Ambrosia, proposes candidate transcription-factor combinations that are then tested experimentally. In the company’s described workflow, RNA instructions are delivered to cells, the cells temporarily produce the factors, and researchers measure molecular and functional changes. (NewLimit’s science overview)
- Cellular age is a biological state inferred from gene expression, epigenetic features or cell behavior.
- Chronological age is the number of years a person has lived.
- Healthspan means years lived in good health; lifespan means total years lived.
- A therapy that improves one organ or treats one disease would not automatically extend lifespan or make the whole body younger.
What NewLimit had shown by the 2025 raise
In a January–February 2025 progress update, NewLimit said that by the end of 2024 it had identified transcription-factor sets that made older human hepatocytes—the principal functional cells of the liver—appear and function more like younger cells. It also said it had formulated a leading hit as a prototype lipid-nanoparticle (LNP) messenger-RNA medicine and observed improved youthful function in a preclinical liver-disease model. (company progress update)
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Those were company-reported laboratory and preclinical findings. They were not results from a completed human clinical trial, and the announcements did not establish human safety, clinical efficacy, durability or a lifespan benefit. Public announcements also do not substitute for the peer-reviewed papers, complete datasets and protocols normally needed to independently assess a therapy.
How the proposed RNA delivery works
- Deliver a temporary RNA instruction with an LNP or related RNA-delivery system.
- Have the target cell produce a selected combination of transcription factors.
- Use those factors to alter gene-regulatory and epigenetic states.
- Test whether specific cellular functions return, rather than relying only on an “age” biomarker.
- Advance promising payloads through manufacturing, toxicology and clinical testing.
NewLimit’s later updates describe continuing LNP-RNA development and candidate selection. (July–August 2025 update; January–February 2026 update)
Why the claim still requires caution
Partial reprogramming is scientifically ambitious because the factors must restore useful function without erasing cell identity or causing uncontrolled growth. Key development risks include:
- Loss of cell identity: reprogrammed cells could move toward an unwanted state.
- Tumor risk: factors connected with proliferation or pluripotency biology make abnormal growth a central safety concern.
- Off-target effects: RNA or transcription factors could affect unintended cells or tissues.
- Delivery and dose: the medicine must reach the right organ and cell type at a controlled exposure.
- Durability: a temporary molecular change may not produce lasting clinical improvement.
- Translation: effects in cultured cells or animals often fail to predict human outcomes.
- Biomarker ambiguity: a younger-looking epigenetic signature is not proof of better health or longer life.
- Regulatory scope: regulators evaluate defined diseases or conditions, not an unrestricted claim to reverse aging.
- Long-term follow-up: therapies that alter gene regulation may require extended safety monitoring.
What changed after the Series B
NewLimit announced an additional $45 million financing on October 20, 2025, involving Eli Lilly, Duke Management Co., Section 32, Abstract and existing investors. The company reported a $1.62 billion valuation cap for that financing. (announcement)
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
On June 2, 2026, it announced a $435 million Series C led by Founders Fund. NewLimit said the money would advance its first aging-reprogramming medicine toward human clinical trials in 2027. It also reported a prototype result in old human liver cells and described manufacturing and biomarker work supporting clinical development. (Series C announcement; May–June 2026 update)
A planned 2027 trial is not the same as an approved, recruiting or completed trial. As of August 18, 2026, NewLimit’s public materials identify no approved product, completed human efficacy study or treatment available for purchase. Its therapeutic materials center on metabolic, vascular and immune systems, with the lead public program focused on hepatocytes and liver function. (therapeutics overview; NewLimit)
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.NewLimit compared with the field
NewLimit is not the only company exploring epigenetic restoration, and the programs are not interchangeable.
| Company | Approach described publicly | Status as of Aug. 18, 2026 | Distinctive focus |
|---|---|---|---|
| NewLimit | RNA-delivered epigenetic-reprogramming payloads | Preparing for a first human trial reportedly planned for 2027 | Metabolic and liver-cell rejuvenation |
| Life Biosciences | Controlled expression of OSK transcription factors | Phase 1 underway; first participant reportedly dosed June 9, 2026 | Defined optic-neuropathy indications |
| Retro Biosciences, Altos Labs, Turn Biotechnologies and others | Various cellular-rejuvenation or reprogramming strategies | Status varies by company and program | Different mechanisms and development stages |
Life Biosciences received FDA authorization to begin first-in-human studies of ER-100 on January 15, 2026, and reported dosing a participant on June 9 in a Phase 1 study for optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. (pipeline; dosing announcement)
How to evaluate “age-reversal” claims
- Financing reality: confirm the round and participants.
- Mechanism: ask whether the biology is coherent and testable.
- Cell evidence: look for relevant human-cell experiments.
- Animal evidence: check whether function or disease improved in an organism.
- Manufacturing: determine whether the payload can be made consistently at clinical scale.
- Regulatory progress: distinguish an authorization or IND clearance from a plan.
- Human safety and efficacy: require results from controlled clinical studies.
- Durability and significance: ask whether benefits persist and improve meaningful disease outcomes, not merely molecular markers.
By that framework, the 2025 announcement established substantial financing and preclinical progress. The 2026 Series C indicated movement toward clinical development, but it did not establish that NewLimit’s approach works in humans.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
